Remicade (infliximab) is a prescription drug that’s used to manage certain autoimmune conditions in adults and some children. The drug is usually given as an intravenous (IV) infusion every 8 weeks.

With billions on the line between pharma giants Johnson & Johnson and Pfizer, an appeals panel upheld a decision to invalidate a key Remicade patent. In a judgment entered Tuesday, the United States ...

If you have a certain type of arthritis or disease that causes inflammation, your doctor may recommend Remicade. It’s a prescription drug used in certain situations to treat: Remicade contains the ...

Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...

The logo of healthcare company Johnson & Johnson is seen in front of an office building in Zug, Switzerland July 20, 2016. REUTERS/Arnd Wiegmann (Reuters) - Johnson & Johnson said a U.S. court had ...

Remicade biologic functions by inhibiting the action of TNF-alpha, a protein involved in inflammation, as it is a tumor necrosis factor (TNF) alpha inhibitor. Biosimilars are FDA-approved versions of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with Crohn’s disease who were biologic naive ...

(Reuters) - U.S. Food and Drug Administration staff members on Friday said Celltrion Inc's biosimilar form of Johnson & Johnson's Remicade arthritis drug appeared "highly similar" to the widely used ...

Inflammatory bowel disease (IBD) is a serious digestive disease of the small intestine and colon; and includes Crohn’s disease and ulcerative colitis. Now, doctors are testing a new use for an ...

Merck & Co. today said it has launched in the U.S. a biosimilar of Remicade ® (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including ...

The global remicade biosimilar market is projected to expand significantly between 2025 and 2035, with a market size growing from USD 2.32 billion in 2025 to USD 4.01 billion in 2035, at a robust ...